Billie Pettersson and Frank R. Lichtenberg - SNS

More documents

Recommendations

Info

Ovan nämnda reformer och styrsystem som tillkommit över åren skapar tillsammansförutsättningarna för tillgänglighet och upptag av nya läkemedel och är därföravgörande för hur väl samhället kan tillgodogöra sig potentialen i nya läkemedel. Fördetta krävs en väl utformad och sammanhållen politik. Därför föreslår vi att densammanlagda effekten av de olika regleringar som införts på området och som kan haeffekt på användning av nya läkemedel under de senaste decennierna utreds och attregelsystemen ses över i syfte att skapa förståelse och underlag för utformning avstyrsystem som kan skapa förutsättning för en optimal användning av läkemedel.6
Executive SummaryLife expectancy around the world has increased dramatically over the past fifty years,while at the same time health care spending has risen substantially. Historically it hasbeen difficult to quantify the relationship between health care spending andimprovements in longevity.We conducted a study to assess the contribution of oneindicator of changes in health care, the introduction of new drugs, to increasedlongevity. New drug launches are of particular interest because they account for asubstantial fraction of medical innovations.We used longitudinal, disease-level data to analyze the impact of pharmaceuticalinnovation on longevity and medical expenditure in Sweden during the period1997−2010. We found that diseases that benefited from more pharmaceutical innovationhad greater increases in longevity. Pharmaceutical innovation accounted for almost onethird (31.6%) of the 1.88-year increase in mean age at death during the period1997−2010. Our models included year and disease fixed effects, so they controlled forthe overall increase in Swedish longevity and for stable between-disease differences inmortality, but not for non-pharmaceutical innovation, which might cause overestimationof the effect from introduction of pharmaceuticals. However, analysis based on U.S.data showed that the rate of pharmaceutical innovation is not positively correlated withthe rate of medical procedure innovation and may be negatively correlated with the rateof diagnostic imaging innovation. This suggests that failure to control for other medicalinnovation is very unlikely to result in overestimation of the effect of pharmaceuticalinnovation on longevity growth, and may even result in underestimation of this effect.We found that longevity depends on the number of drugs (substances) to treat a disease,not the number of chemical subgroups (drug classes) developed to treat the disease.Diseases that experienced more pharmaceutical innovation saw smaller increases inhospital use. New drugs have been cost saving: the reduction in annual hospitalexpenditure induced by pharmaceutical innovation has been greater than the inducedincrease in annual pharmaceutical expenditure. New drugs have reduced lifetimemedical expenditure, despite the fact that they increased life expectancy by 6 monthsduring 2000−2009.One limitation of this study is that while it does provide information about medicines onan aggregate level, it does not indicate medicines in which to invest. Another limitationis that the outcome measure is related to longevity, which is indeed a widely usedindicator of the health of a population, but it reflects the quantity rather than quality oflife. Many medicines mainly improve quality of life and this will not be covered in ourstudy. Nevertheless, the conclusion is that new pharmaceuticals, on an aggregate level,are an important production factor in health care.The uptake and use of (new) medicines is determined by policies at several levels: at themacro or healthcare system level, the service organization level and the clinical practicelevel. During the last two decades a variety of pharmaceutical policies has beenintroduced in Sweden, which might have had an impact on the use of new medicines,but no thorough and complete review of these polices has yet been carried out. Thereare potential new pharmaceuticals that increase life expectancy and/or lead to reduceduse of other resources. It is important to prioritize so that resources could be allocated tothese products. Pharmaceutical policies should be balanced to allow society as well as7
Page 5: undersöks är relaterat till över
Page 9 and 10: 1. IntroductionLongevity has consta
Page 11 and 12: 2. Background2.1. Determinants infl
Page 13 and 14: 2.3. Access, uptake and use of (new
Page 15 and 16: 3. Value of innovationIncreased lon
Page 17 and 18: Figure 1. Mean age at death: Actual
Page 19 and 20: Table 1. Estimation of incremental
Page 21 and 22: This could be explained by the fact
Page 23 and 24: is not positively correlated with t
Page 25 and 26: incremental innovation and on dynam
Page 27 and 28: 18. Godman, B., Sakshaug, S., Berg,
Page 29 and 30: 56. Bertrand, M., Duflo, E., Mullai

Billie Pettersson and Frank R. Lichtenberg - SNS

Create successful ePaper yourself

Delete template?

Save as template?